HRSA-23-038: Rural Communities Opioid Response Program – Overdose Response
Closed
This grant is closed. A newer notice from the same program is forecast: Rural Communities Opioid Response Program - Overdose Response (HRSA-27-040). Status: Expected deadline March 10, 2027. It is in our archive of Health Resources and Services Administration notices from 2022.
Health Resources and Services Administration offered grants to nonprofits, colleges and universities, state and local governments and tribes. It expected to make about 40 awards worth $12.0 million in total. Applications closed on January 19, 2023.
From the official notice on Grants.gov, last changed October 21, 2022. Checked November 7, 2026.
- Total funding$12.0 million
- Expected awards40
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HRSA-27-040 | August 21, 2026 | Expected deadline March 10, 2027 | Forecast |
| HRSA-25-010 | December 20, 2024 | Closed March 10, 2025 | Closed |
Key dates
| Posted | October 21, 2022 |
|---|---|
| Deadline | January 19, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments and tribes.
All 11 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include all domestic public or private, non-profit or for-profit entities, including community-based organizations, federally recognized tribes, tribal organizations, state, local and territorial governments, and institutions of higher education.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Rural Communities Opioid Response Program-Overdose Response program. The Rural Communities Opioid Response Program (RCORP) is a multi-year HRSA initiative aimed at reducing the morbidity and mortality of substance use disorder (SUD), including opioid use disorder (OUD), in high-risk rural communities. This funding opportunity, RCORP-Overdose Response, will advance RCORP’s overall goal by supporting immediate responses to the opioid crisis in rural areas. Over the course of a one-year period of performance, RCORP-Overdose Response recipients will address immediate needs in rural areas through improving access to, capacity for, and sustainability of prevention, treatment, and recovery services for substance use disorder (SUD). To achieve the purpose of the RCORP-Overdose Response program, applicants must select from a list of allowable activities. Please see Program Requirements and Expectations for additional information. Applicants are encouraged to give special consideration to the needs of rural populations that have historically suffered from poorer health outcomes or health disparities, as compared to the rest of the rural population. Examples of these rural populations include, but are not limited to: racial and ethnic minorities, people who are pregnant, adolescents and youth, LGBTQIA+ individuals, veterans, socioeconomically disadvantaged populations, the elderly, and individuals with disabilities.
Who has won Rural Healthcare Services Programs grants before
From fiscal 2021 to 2025, Rural Healthcare Services Programs (93.912) awarded $727 million across 1,490 grant awards, an average of $487,643 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Rural Health Resource Center | Minnesota | 3 | $58.6 million |
| University of North Dakota | North Dakota | 3 | $10.3 million |
| JBS International, Inc. | Maryland | 1 | $10.1 million |
| Arkansas Rural Health Partnership | Arkansas | 6 | $8.3 million |
| Rural Health Redesign Center Organization, Inc. | Pennsylvania | 3 | $7.9 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-040, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-23-038 still open?
No. It closed on January 19, 2023. A newer notice is forecast: HRSA-27-040, expected deadline March 10, 2027.
Who can apply for Rural Communities Opioid Response Program – Overdose Response?
Health Resources and Services Administration accepted applications from nonprofits, colleges and universities, state and local governments and tribes. The notice adds further conditions, so read its eligibility section.
What is the deadline for Rural Communities Opioid Response Program – Overdose Response?
Closed January 19, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $12.0 million in total across about 40 awards.
Who has won Rural Healthcare Services Programs grants before?
The largest recipients over five fiscal years were Rural Health Resource Center, University of North Dakota, JBS International, Inc. The program made 1,490 awards worth $727 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)